COLL Profile
Collegium Pharmaceutical Inc. (COLL) is a pharmaceutical company that specializes in developing and commercializing innovative treatments for chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts, and was founded in 2002.
Collegium's flagship product is Xtampza ER, an extended-release oral formulation of oxycodone. Xtampza ER is designed to deter abuse and misuse, and is approved by the FDA for the management of pain severe enough to require daily, around-the-clock opioid treatment. Collegium also markets Nucynta ER, an extended-release oral formulation of tapentadol, for the management of pain severe enough to require daily, around-the-clock opioid treatment.
In addition to Xtampza ER and Nucynta ER, Collegium has a pipeline of product candidates in various stages of development. These include COL-172, a preclinical-stage program for the treatment of chronic cough, and a Phase 1 program for the treatment of postoperative pain.
The company's business model is based on licensing its proprietary technology to third-party partners, who are responsible for manufacturing and commercializing the products. Collegium receives revenue from the licensing agreements and from product royalties. The company also has a dedicated sales force that promotes its products directly to healthcare providers.
|
